Abpro Holdings, Inc. · OTC:ABPO
Abpro — Atlantic Coastal Acquisition Corp. II — SPAC Merger (April 2024)
44 slides from Abpro's SPAC merger presentation, Apr 3, 2024
Slide 1: Corporate Presentation April 2024
Exhibit 99.1 Corporate Presentation April 2024
Slide 2: Disclaimers
2 Disclaimers This presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Abpro Corporation (“Abpro”) and Atlantic Coastal Acquisition Co
Slide 3: Disclaimers: Additional Information and Where to Find It
3 Disclaimers Additional Information and Where to Find It This document relates to the Proposed Business Combination between Abpro and ACAB. ACAB filed a registration statement on Form S-4 relating to the Proposed Business Combination (the “Registration Statement”) which will includes a proxy statem
Slide 4: Table of Contents
44 Transaction Overview Investment Highlights 1 2 Pipeline and Technology Experienced Team 3 4 Platforms Table of Lead Candidates Additional Pipeline Contents 5 6 Candidates Program Development Appendix 7 8 Timeline
Slide 5: Key Presenters
5 5 Key Presenters Miles Suk Shahraab Ahmad Ian Chan CEO CEO & Co-Founder Board Member Atlantic Coastal Acquisition Abpro Corporation Abpro Corporation Corp. II (ACAB)
Slide 6: Transaction Overview
6 Transaction Overview Atlantic Coastal Acquisition Corp. II (NASDAQ: ACAB) plans to conduct a Pro Forma Valuation at Close business combination with Abpro Corporation (“Abpro“) at a purchase price of approximately $500 million (USD millions, except for share data) • Transaction expected to be funde
Slide 7: Investment Highlights
7 Investment Highlights Proprietary Antibody Platform Robust Therapeutic Pipeline of Next Generation Candidates ® • Antibody Discovery: DiversImmune Candidate Indication TM • Antibody Engineering: MultiMab • ABP-102(HER2/CD3) Breast and gastric cancer • ABP-201(VEGF/ANG2) Wet AMD and DME • ABP-110(G
Slide 8: Experienced Leadership Team
8 Experienced Leadership Team Christian Zapf, JD, MBA Richard Mitrano Ian Chan, MBA Eugene Chan, MD Robert Markelewicz, MD SVP of Corporate Development SVP of Finance CEO, Co-founder Chairman, Co-founder Chief Medical Officer & General Counsel Brown AB; Harvard MBA Harvard AB; Harvard MD Brown ScB,
Slide 9: Atlantic Coastal Management Team
9 Atlantic Coastal Management Team Shahraab Ahmad Burt Jordan Jason Chryssicas Tony Eisenberg President Chairman, CEO CFO CSO
Slide 10: Experts on Boards
10 10 Experts on Boards 1 2 2 Robert Langer, PhD Laurie Glimcher, MD Ron Levy, MD David H. Koch Institute Professor, MIT; President and CEO, Professor and Chief, Founder of Moderna, BIND, Dana-Farber Cancer Institute Division of Oncology, Momenta, AIR, others Stanford School of Medicine 2 2 2 George
Slide 11: Pipeline with Next Generation Candidates
11 Pipeline with Next Generation Candidates TOTAL INDICATION PROGRAM TARGET PRECLINICAL IND-ENABLING PHASE 1 PHASE 2 PHASE 3 ADDRESSABLE MARKET 1 DME/Wet AMD Anti-VEGF/ANG2 ABP-201 $10.4 Billion Breast, Gastric 2 Anti-HER2/CD3 ABP-102 $12.1 Billion Cancer 3 Liver Cancer Anti-GPC3/CD3 ABP-110 $12.9 B
Slide 12: Technology Platform
TECHNOLOGY PLATFORM
Slide 13: DiversImmune Discovery Platform
® 13 13 Diversimmune Discovery Platform Features: • Rapid Generation Creates antibody therapies against traditionally Proprietary antibody discovery platform difficult targets that seeks to swiftly produce a diverse array of antibodies Validated by global pharma and research institutions • Target Va
Slide 14: MultiMab Antibody Engineering Platform and TetraBi Format
TM 14 14 MultiMab Antibody Engineering Platform and TetraBi Format Anticipated Advantages of TetraBi Format: 1 Enhancing efficacy and safety: fine-tuning antibody product • Bivalent binding to TAA for potentially formats for optimal results increased efficacy • Fc modification for reducing toxicity
Slide 15: Lead Programs
LEAD PROGRAMS • ABP-102 • ABP-201
Slide 16: ABP-102 HER2/CD3 T-Cell Engager
ABP-102 HER2/CD3 T-Cell Engager Treatment for HER2+ Breast Cancer & Gastric Cancer
Slide 17: ABP-102: Strategic Partnership with Celltrion
17 17 ABP-102: Strategic Partnership Global Development & with Celltrion Commercialization Partnership Highlights Leading biopharmaceutical company headquartered in Incheon, South Korea; KRX: 068270 Fully Funded Anticipated Development Plan • Celltrion funds all development costs, including preclini
Slide 18: ABP-102: Addressing Unmet Needs in HER2+ Cancers
18 Potential benefits of Potential Competitive ABP-102 in immuno- Advantages: Addressing Unmet oncology Needs in HER2+ • Activating T cells to kill tumor cells • Current HER2-directed therapies have Cancers Treatment: demonstrated increased chemical off TetraBi antibody targets HER2 on target toxici
Slide 19: ABP-102: Next generation T-cell engager for HER2+ solid tumors
HER2 19 19 ABP-102: Next generation T-cell engager for HER2+ solid tumors HER2-high CD3 (Humanized and Cyno Cross-Reactive) Key Characteristics: • Dual-arm affinity-tuned construct for selective killing and cytokine release on HER2-high target cells, with reduced killing and cytokine release on HER2
Slide 20: ABP-201 VEGF/ANG-2 Bispecific Antibody
ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODY Treatment for Diabetic Macular Edema (“DME”) & Wet Age-related Macular Degeneration (”AMD”)
Slide 21: Addressing Unmet Needs in Wet AMD/DME Treatment: ABP-201
21 21 Addressing Unmet Needs in Wet AMD/DME Treatment: ABP-201 • We believe that ABP-201 will Competitive Landscape require less frequent dosing, providing a significant $10.4 billion advantage in the commercial Global Wet AMD market setting. 1 size projection in 2024 • We anticipate that ABP-201 wi
Slide 22: ABP-201: Anti-VEGF/ANG2
22 ABP-201: Anti-VEGF/ANG2 Target Indication: Wet AMD/DME Key Characteristics • Dual inhibition of VEGF and ANG-2 to block angiogenesis ABP-201 • Four high-affinity binding sites for increased potential potency • Dual targeting in single molecule for simultaneous inhibition • Natural antibody struct
Slide 23: ABP-201: Positive Results in Preclinical Models
23 ABP-201: Positive Results in Preclinical Models Mean total ocular examination scores over 1 Mean Intraocular pressure over time 1 time ABP-201 does not induce significant inflammation or intraocular pressure increases in preclinical models OE Scores range from 0(no abnormalities) to a maximum of
Slide 24: ABP-201 Current Status and Development Plan
24 24 Current Status: • Investigation New Drug (IND) enabling studies underway Anticipated Development Plan • Q1 2026: File IND application and Initiate a Phase 1 trial in patients with ABP-201 Wet AMD Development • Following the identification of the Collaboration Highlights: Strategy maximum toler
Slide 25: Additional T-Cell Engagers
ADDITIONAL T-CELL ENGAGERS ABP-150: Anti-Claudin 18.2/ CD3 against Gastric Cancer ABP-110: Anti-GPC3/CD3 against Liver Cancer
Slide 26: ABP-150: Anti-Claudin18.2/CD3
26 ABP-150: Anti-Claudin18.2/CD3 Target Indication: Gastric Cancer $13.11 billion Key Characteristics • T-cell engager designed to fight cancer through co-targeting CD3 & Claudin 18.2 Global gastric cancer market 2 size projection by 2029 • Specific for Claudin 18.2, avoiding binding closely related
Slide 27: ABP-150: in vivo Efficacy and Safety Profile in Preclinical Models
27 ABP-150: in vivo Efficacy and Safety Profile in Preclinical Models 1 Potent in vivo efficacy in gastric cancer ABP-150 is well tolerated in a preclinical tox model 1 xenograft mouse model Body weights Temperatures 24 38.0 ABP-150 17 mg/kg ABP-150 17 mg/kg ABP-150 1.7 mg/kg ABP-150 1.7 mg/kg 37.5
Slide 28: ABP-110: Anti-GPC3/CD3
28 28 ABP-110: Anti-GPC3/CD3 Target Indication: Hepatocellular Carcinoma- Liver Cancer Designed to provide in-vitro T-cell + 2 + 2 HEP3B tumors + CD8 T cells HEPG2 tumors + CD8 T cells dependent cellular cytotoxicity 60 100 (TDCC) against liver cancer cells YP7 x CD3 YP7 x CD3 80 3BN9 x CD3 3BN9 x C
Slide 29: Anticipated Clinical Development Timeline
29 Anticipated Clinical Development Timeline Timeline 2025 2026 2026 2027 2027 2028 2028 2029 2029 2030 2030 2031 and Beyond 2H 1H 2H 1H 2H 1H 2H 1H 2H 1H 2H ABP-102 BLA Phase 1 Phase 2 Phase 3 BLA- ABP-201 Phase 1 Phase 2 Phase 3 2034 1H BLA- ABP-150 Phase 1 Phase 2 Phase 3 2032 2H BLA- ABP-110 Pha
Slide 30: Appendix
• Additional Data for Abpro Technology Platform • Additional Key Team Members Appendix • Additional Data for ABP-102(HER2/CD3) • Additional Data for ABP-201(VEGF/ANG2)
Slide 31: Additional Data for Abpro Technology Platform
Additional Data for Abpro Technology Platform 31
Slide 32: DiversImmune Platform Case Study: Amyloid
32 32 Diversimmune Platform Case study: Amyloid*: Preclinical results from functional therapeutic antibodies ® generated with DiversImmune platform, via a project for GSK, 1 published in Nature and The New England Journal of 2 Medicine Abpro generated a therapeutic mAb “Abp1” against Amyloid used by
Slide 33: Neutralizing Antibody Discovery Platform
33 Neutralizing Antibody B cell Cloning Discovery Platform Timeline: < 2 months Neutralizing Target-specific Paired H/L cDNA NGS B Cell isolation Activity memory B cells by barcoding sequencing Convalescent /immunized human Humanized mice subjects A strategy to enrich only the B cells that Cloning a
Slide 34: Anticipated Advantages of TetraBi Format Over First- and Second-Generation T-Cell Engagers
34 Anticipated Advantages of TetraBi Format Over First- and Second-Generation T-Cell Engagers nd st 1 Generation 2 Generation Abpro Antibody Bispecific Bispecific TetraBi Benefit Characteristics Stronger binding to the tumor cell, potentially leading Bivalent Binding to to increased efficacy and an
Slide 35: Additional Key Team Members
Additional Key Team Members 35
Slide 36: Additional Key Team Members
36 Additional Key Team Members Askar Kuchumov, PhD Awo Kankam Shaun Murphy, PhD Mengsha Wang, MBA VP of Business VP of Clinical Operations; VP of Immunology Director of Corporate Development Head of Program Management Development Clark U MSc. Finance, MBA Lomonosov Moscow State, BS Cranfield UK, Bro
Slide 37: Additional Data for ABP-102 HER2/CD3 T-Cell Engager
Additional Data for ABP-102 HER2/CD3 T-Cell Engager 37
Slide 38: ABP-102: TetraBi antibodies exhibit selectivity in vitro
ABP-102: engineered TetraBi antibodies exhibit selectivity in vitro, with potent 38 cytotoxicity on HER2-high cell lines and reduced killing of HER2-low cell lines HER2 expression level High Intermediate Trastuzumab binding by flow cytometry results in a 1 range of HER2 expressing cancer cell lines.
Slide 39: ABP-102: functional selectivity for T cell activation
ABP-102: engineered TetraBi antibodies exhibit functional selectivity for T cell 39 activation, including reduced cytokine release for HER2-low expressing cell lines HER2 high HER2 low ABP-102-mediated PBMC cytotoxicity of HER2-high (SKBR3) ABP-102-mediated cytokine release (IL-2, IFNg, IL-6, TNFa)
Slide 40: Additional Data for ABP-201 VEGF/ANG-2 Bispecific Antibodies
Additional Data for ABP-201 VEGF/ANG-2 BISPECIFIC ANTIBODIES 40
Slide 41: ABP-201 Exhibits Favorable PK Compared with Vabysmo
41 ABP-201 Exhibits Favorable PK Compared with Vabysmo 1 Faricimab(RG7716) 0.5 mg dose in Cyno PK parameter Unit Serum Aqueous C µg/ml 3.8 99 max t h 24 72 max t h 89.3 68 1/2 Faricimab PK in t h 672 672 last Cyno AUC (ug*h)/ml 295 18100 0-tlast AUC (ug*h)/ml 296 18200 0-inf F % 12.7 N/A vs. 2 ABP-2
Slide 42: ABP-201 Exhibits Favorable PK Compared with Eylea
42 ABP-201 Exhibits Favorable PK Compared with Eylea 1 ABP-201 0.2mg dose in Rabbit PK parameter Unit Serum Aqueous Vitreous Retina C µg/ml 0.415 14.374 183.357 8.457 max t h 48 48 1 24 max t h 38 108 82 106 1/2 AUC (ug*h)/ml 52 2529 36922 1777 0-tlast AUC (ug*h)/ml 55 2557 37027 1795 0-inf MRT (h)
Slide 43: Certain Risks Related to ACAB, Abpro and the Business Combination
43 Certain Risk Related to ACAB, Abpro and the Business Combination All references to the “Company,” “we,” “us” or “our” refer to the business of Abpro Corporation. and its subsidiaries, taken as a whole, unless the context otherwise requires. The risks noted below are not exhaustive and are qualifi
Slide 44: Thank you!
Mission: Developing antibody therapies to improve the lives of patients Thank you! facing severe and life- threatening diseases https://abpro.com/ IR@abpro.com ABPRO CORPORATION 68 Cummings Park, Woburn, MA 01801
Atlantic Coastal Acquisition Corp. II — SPAC Merger (April 2024) on 6ix